New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2014
05:13 EDTCTICCTI announces GOG completes enrollment in Phase 3 trial of paclitaxel poliglumex
Cell Therapeutics announced that the Gynecologic Oncology Group, or GOG, informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex as maintenance therapy in ovarian cancer. The trial is being conducted and managed by the GOG, which is one of the National Cancer Institute's funded cooperative cancer research groups focused on the study of gynecologic malignancies.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
11:21 EDTCTICIncyte rises after competitor drug put on hold by FDA
Shares of Incyte (INCY) are rising after a competitor's myelofibrosis drug was placed on full clinical hold by the FDA. WHAT'S NEW: CTI BioPharma (CTIC) announced Tuesday night that it received notice from the FDA that its Investigational New Drug Application for pacritinib had been placed on full clinical hold. Under the full clinical hold, all patients currently on pacritinib must discontinue the drug immediately and no patients can be enrolled or start pacritinib as initial or crossover treatment. CTI BioPharma withdrew its New Drug Application until the company has had a chance to review the safety and efficacy data from the PERSIST-2 Phase 3 clinical trial and decide next steps. Previously, on February 8, CTI BioPharma had announced the drug was on partial clinical hold. ANALYST REACTION: Leerink analyst Michael Schmidt said that while he didn't view CTI BioPharma's pacritinib as a significant threat to Incyte's Jakafi franchise in myelofibrosis, he believes the "surprising" setback of a potential competitor should remove a small overhang on Incyte shares. Leerink has an Outperform rating and $118 price target on Incyte shares. Meanwhile, CTI BioPharma was downgraded by analysts at Piper Jaffray, WallachBeth and Ladenburg. Among them, WallachBeth's Bob Ai downgraded CTI to Sell with a 0c price target, saying he sees no reason to hold the stock. PRICE ACTION: Shares of Incyte gained 3.4% to $74.71 in late morning trading, while shares of CTI BioPharma plunged 41% to 29c.
10:01 EDTCTICOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Antero Resources (AR) downgraded to Neutral from Buy at Goldman... Apollo Investment (AINV) downgraded to Sell from Neutral at Citi... BBA Aviation (BBAVY) downgraded to Neutral from Buy at Goldman... CM Finance (CMFN) downgraded to Outperform from Strong Buy at Raymond James... CTI BioPharma (CTIC) downgraded to Sell from Hold at WallachBeth... Calix (CALX) downgraded to Market Perform from Outperform at Cowen... ConocoPhillips (COP) downgraded to Peer Perform from Outperform at Wolfe Research... Fifth Street Finance (FSC) downgraded to Neutral from Overweight at JPMorgan... Fortis (FRTSF) downgraded to Neutral from Outperform at Credit Suisse... ITC Holdings (ITC) downgraded to Market Perform from Outperform at Wells Fargo... KapStone (KS) downgraded to Hold from Buy at Deutsche Bank... Knight Transportation (KNX) downgraded to Hold from Buy at Evercore ISI... Lake Shore Gold (LSG) downgraded to Sector Performer from Outperformer at CIBC... Medley Capital (MCC) downgraded to Hold from Buy at Jefferies... Pandora (P) downgraded to Market Perform from Outperform at Cowen... Parker-Hannifin (PH) downgraded to Hold from Buy at Evercore ISI... Parkway Properties (PKY) downgraded on real estate headwinds, valuation at Stifel... Plains GP Holdings (PAGP) downgraded to Neutral from Outperform at Credit Suisse... Ruckus Wireless (RKUS) downgraded to Neutral from Buy at SunTrust... SolarCity (SCTY) downgraded to Neutral from Buy at Roth Capital... Tahoe Resources (TAHO) downgraded to Sector Perform from Outperform at RBC Capital... USANA (USNA) downgraded to Neutral from Buy at DA Davidson... Valero (VLO) downgraded to Buy from Conviction Buy at Goldman... Western Union (WU) downgraded to Neutral from Outperform at Macquarie... XL Group (XL) downgraded to Sell from Hold at Deutsche Bank.
09:19 EDTCTICOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Akamai (AKAM), up 16.5%... Prospect Capital (PSEC), up 10.7%... Panera Bread (PNRA), up 2%. ALSO HIGHER: Deutsche Bank (DB), up 6.1% after the Financial Times reported that the company is considering a multibillion bond buyback... Fitbit (FIT), up 3.7% after Marc Benioff reported a 5% stake in the company... FireEye (FEYE), up 3.9% after being upgraded to Buy from Neutral at BTIG... Shire (SHPG), up 1.7% after being upgraded to Outperform from Sector Perform at RBC Capital. DOWN AFTER EARNINGS: Time Warner (TWX), down 7.6%... Disney (DIS), down 5.1%... SolarCity (SCTY), down 27.8%. ALSO LOWER: CTI BioPharma (CTIC), down 38% after the FDA placed pacritinib IND on full clinical hold... Mast Therapeutics (MSTX), down 40.1% after 29.1M share Spot Unit offering priced at $0.275.
09:16 EDTCTICCTI BioPharma downgraded to Neutral from Buy at Ladenburg
Subscribe for More Information
08:20 EDTCTICPacritinib hold an incremental positive for Incyte, says Leerink
Subscribe for More Information
06:47 EDTCTICCTI BioPharma downgraded to Sell from Hold at WallachBeth
Subscribe for More Information
05:58 EDTCTICCTI BioPharma downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
05:17 EDTCTICCTI BioPharma says FDA placed pacritinib IND on full clinical hold
Subscribe for More Information
February 8, 2016
09:17 EDTCTICOn The Fly: Pre-market Movers
HIGHER: Apollo Education (APOL), up 26.6% after announcing that it will be acquired for $9.50 per share... Sprouts Farmers Market (SFM), up 5% after being added to S&P 400... GoPro (GPRO), up 3.4% after signing a licensing agreement with Microsoft (MSFT). LOWER: BioCryst Pharmaceuticals (BCRX), down 60.9% after reporting OpuS-2 clinical trial results... CTI BioPharma (CTIC), down 55.4% after the FDA placed a partial clinical hold on pacritinib studies... Tableau (DATA), down 5.5% after being downgraded to Equal Weight at Morgan Stanley... HSBC (HSBC), down 3.6% after being downgraded to Underweight from Equal Weight at Morgan Stanley... Chesapeake Energy (CHK), down 21% after Hedgeye analyst Kevin Kaiser said in an interview with Barron's that Chesapeake could go to zero... Twitter (TWTR), down 2.9% after backlash over its new algorithmic timeline.
05:25 EDTCTICCTI BioPharma completes enrollment in PERSIST-2 Phase 3 clinical trial
CTI BioPharma announced that as of February 3, it has completed patient enrollment in the PERSIST-2 Phase 3 clinical trial of pacritinib for the treatment of patients with myelofibrosis. PERSIST-2 is evaluating pacritinib for patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter. Under the FDA partial clinical hold referenced above, patients currently receiving pacritinib may continue to do so unless they are not deriving benefit after 30 weeks of pacritinib treatment, and crossover of patients from the control arm to the pacritinib arm will not be allowed.
05:24 EDTCTICCTI BioPharma says FDA places partial clinical hold on pacritinib studies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use